(Q44553482)

English

Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial

scientific article published in July 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Helicobacter pylori

object named as

Helicobacter pylori

1 reference

based on heuristic

inferred from title

author name string

T Fujioka

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

T Arakawa

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

T Shimoyama

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

T Yoshikawa

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

M Itoh

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

M Asaka

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

H Ishii

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

H Kuwayama

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

R Sato

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

S Kawai

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

T Takemoto

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

K Kobayashi

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

18 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

146-152

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Antibacterial treatment of gastric ulcers associated with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Chronic active gastritis after eradication of Campylobacter (now: Helicobacter) pylori. Results of a medium term follow-up study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Numerical aberrations of chromosomes 16, 17, and 18 in hepatocellular carcinoma: a FISH and FCM analysis of 20 cases

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Campylobacter pylori detected noninvasively by the 13C-urea breath test

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.18.S1.20.X

21 January 2018

Identifiers

10.1046/J.1365-2036.18.S1.20.X

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44553482&oldid=2027708822"